Condition evidence map
Sarcopenic obesity and lean-mass concerns
Research evidence map for the lean-mass component of weight reduction with incretin therapy, especially in older adults and those with low baseline muscle mass.
Research context
All weight reduction — diet, surgery, pharmacotherapy — loses some lean mass alongside fat mass. DXA substudies of pivotal incretin trials report lean-mass loss broadly proportional to diet-based weight loss of similar magnitude. The clinical question is whether older adults, frail patients and those with sarcopenic obesity are at materially greater risk and how to support muscle and bone during therapy.
Why this matters metabolically
Sarcopenia compounds cardiometabolic risk and increases fall, fracture and functional-decline risk. Weight-management pathways increasingly include lean-mass monitoring, protein intake guidance and resistance-activity recommendations during therapy.
FAQs
- Should patients on GLP-1 therapy do resistance training?
- UK specialist weight-management practice increasingly advises adequate protein intake and resistance activity during weight reduction. Individual care plans should be discussed with the prescriber or specialist team.
- Trial DXA data may not generalise to older or frail populations.
- Lean-mass loss with therapy is not unique to incretin agents.
Related mechanisms
Related peptide profiles
Related trials
Related safety signals
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site